Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness
Plus: China Starts Vaccines Pre-Order
Executive Summary
J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.
You may also be interested in...
J&J's Gorsky On Janssen's COVID-19 Vaccine Timeline, Scale-Up and Back Story
The company is on track to provide hundreds of millions of doses of its COVID-19 vaccine in the first half of 2021, Gorsky reaffirmed during the Milken Institute Future of Health Summit.
Lack Of Details On J&J COVID Vaccine Trial Safety Pause Raises ACIP Concerns About Transparency
Patient confidentiality and trial blinding precluded a Janssen official from sharing specifics about the safety event that led to a study enrollment pause, but Advisory Committee on Immunization Practices representatives say the lack of detailed, publicly disclosed information is not helping vaccine confidence.
Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused
NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.